Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER Trial)

The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized 27,564 patients with established atherosclerotic cardiovascular disease and LDL-C ≥70 mg/dL on optimized statin therapy to evolocumab or placebo, with a median follow-up of 2.2 years.

Evolocumab reduced LDL-C by 59% — from a median baseline of 92 mg/dL to 30 mg/dL at 48 weeks. At these achieved levels, 87% of patients reached LDL-C ≤70 mg/dL and 42% reached ≤25 mg/dL. The composite primary endpoint (CV death, MI, stroke, unstable angina hospitalization, coronary revascularization) was reduced by 15% (HR 0.85, p<0.001). The key secondary endpoint of CV death, MI, and stroke was reduced by 20% (HR 0.80, p<0.001). Importantly, the absolute benefit increased over time — from a 16% relative risk reduction in year 1 to 25% beyond year 1 — consistent with the cumulative burden hypothesis of atherosclerosis.

No significant reduction in cardiovascular mortality was observed over the 2.2-year median follow-up, a limitation acknowledged by the investigators as reflecting insufficient follow-up time for mortality benefit to emerge with the event rates and sample size of the trial.

FOURIER is the definitive proof-of-concept trial for aggressive LDL-C lowering below statin targets. It established that reducing LDL-C to 30 mg/dL is safe (no evidence of neurocognitive harm, no new safety signals at very low LDL-C) and that the LDL-cardiovascular risk relationship continues to operate at LDL-C levels well below 70 mg/dL. Combined with GLAGOV (plaque imaging), ODYSSEY Outcomes, and Mendelian randomization evidence, FOURIER defines the current upper bound of established evidence for aggressive LDL-C lowering in secondary prevention.

We rate the evidence strong. The landmark PCSK9 inhibitor outcomes trial confirming cardiovascular event reduction with evolocumab — defining the current standard for secondary prevention in high-risk patients not at LDL-C goal on statins.